Morgan Stanley Upgrades Pharvaris to Overweight, Raises Price Target to $34
Portfolio Pulse from richadhand@benzinga.com
Morgan Stanley analyst Matthew Harrison has upgraded Pharvaris (NASDAQ:PHVS) from Equal-Weight to Overweight and raised the price target from $10 to $34.
August 15, 2023 | 9:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pharvaris has been upgraded to Overweight by Morgan Stanley, with a raised price target of $34, up from $10.
The upgrade from Morgan Stanley is a positive signal for Pharvaris. The raised price target indicates that the analyst sees significant upside potential in the stock, which could drive investor interest and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100